Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A sandwich enzyme immunoassay was set up to measure tumor associated antigen (antigen PA8-15) detected by monoclonal antibody PA8-15. The cut-off value was set at 55 U/ml. Tests on 437 sera samples from patients with malignant or benign diseases yielded the following positive percentages: esophageal cancer, 9.1%; gastric cancer, 23.1%; colorectal cancer, 44.8%; hepatoma, 32.6%; biliary tract cancer, 47.5%; pancreatic cancer, 84%; lung cancer, 30.8%; breast cancer, 16%; benign diseases, 13.2%. Positive antigen PA8-15 levels in patients with gastric, colorectal and pancreatic cancers, increased with the progression of clinical stage. When antigen PA8-15 was monitored in 11 various cancer cases before and after surgery, a decrease in PA8-15 value was revealed in all resected patients postoperatively, whereas a more than 100% increase in PA8-15 values was noted in non-resected patients. Compared with CEA and CA19-9, the highest positive PA8-15 rate was seen in pancreatic cancer patients. By combining the rates of positive sera obtained with each tumor marker, the overall percentage increased. These results suggest that measuring serum PA8-15 levels will aid in serological cancer diagnoses, particularly pancreatic cancer.
 ...
PMID:Detection of tumor associated antigen, PA8-15, in sera from pancreatic and gastrointestinal carcinoma patients. 237 Jun 93

A 72-year-old female underwent surgical resection of lung cancer and mediastinal tumor. Abnormal shadows on the chest roentgenogram were incidentally detected by the regular health screening. The lung cancer existed in the left upper lobe, and the mediastinal tumor existed in the posterior mediastinum along left side of the spines. Serum CEA level was 299 ng/ml by enzyme immunoassay method. We judged the lung cancer as being in Stage I (T2 N0 M0), and the mediastinal tumor as benign neurogenic tumor unrelated to the lung cancer through detailed examination. Surgical resection of both tumors was performed through left thoracotomy, and the surgical procedure was curative operation. Pathological examination revealed the lung cancer was moderately differentiated adenocarcinoma and the mediastinal tumor was Schwannoma. Eight months after surgery, serum CEA level is 1.1 ng/ml without evidence of recurrence. This experience suggested us that a mediastinal tumor accompanied by lung cancer is not necessarily metastatic tumor, and that curative operation may be possible in these cases.
 ...
PMID:[A case of lung cancer with mediastinal tumor]. 238 25

The object of present study is to investigate the clinical value of BFP and CEA in stomach and lung cancer. BFP-positive cases were found in 36.8% of 378 stomach cancer and in 65.2% of 89 lung cancer. CEA-positive cases revealed in 37.6% of 205 stomach cancer and in 65.6% of 64 lung cancer. In serum levels of BFP, there was no difference between differentiated type and undifferentiated type of stomach cancer by histological classification. In lung cancer, BFP levels in serum of large cell type were significantly higher than those of other types. The combination assay using BFP and CEA revealed 54.1% and 82.8% positive rate of stomach cancer and lung cancer, respectively. These results suggested that BFP and CEA assay appeared to be available for elevation of cancer diagnosis, especially useful for diagnosis of lung cancer.
 ...
PMID:[Clinical investigation of basic fetoprotein (BFP) and carcinoembryonic antigen (CEA) in stomach cancer and lung cancer]. 241 61

Immunohistologic markers have been of considerable value in differentiating malignant mesothelioma from adenocarcinoma. Recently, staining for milk-fat globule (MFG) protein has been suggested as a useful diagnostic test for this separation, but subsequent reports have been conflicting, with some authors finding clearcut differences, while others showed similar marking of both tumor types. To examine this technique further, we studied lung carcinomas and mesotheliomas with commercially available anti-MFG, and compared these results with those obtained with anticarcinoembryonic antigen (CEA), a commonly used immunomarker of carcinoma. We found that carcinomas showed strong cytoplasmic staining for MFG and CEA; however, a greater percentage of carcinomas were more strongly positive for CEA than for MFG. Mesotheliomas did not, for the most part, stain strongly with either antibody. In addition, carcinomas from different hospitals stained differently for MFG, but not for CEA. We conclude that although strong cytoplasmic staining for MFG is a reasonably reliable indicator of carcinoma, CEA staining provides a better separation and is considerably easier to interpret in lung cancer specimens.
 ...
PMID:Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. 243 59

Comparison of basic fetoprotein (BFP) with 10 other tumor markers was made with sera from 549 patients with benign diseases and 870 patients with cancers, using BFP-EIA kit and commercial kits for others. BFP-positive rates higher than CEA or CA19-9 were found in various cancers except CEA in cancer of the colon, pancreas and lung, or CA19-9 in cancer of pancreas and bile duct. Furthermore, BFP showed higher positive rates in comparison with AFP in cancer of liver and testis, SLX(sialyl SSEA-1) or SCC in lung cancer and CA125 in uterine cancer. The correlation coefficient of BFP with other tumor markers except for SCC in lung cancer were low (below 0.262) in cancer and benign diseases. The combined assay of BFP with some other makers such as CEA in cancer of the digestive organ, lung, markers ovary and uterus, CA19-9 in cancer of the bile duct and lung, CA125 in ovarian cancer, AFP in cancer of the liver and testis, and PAP in prostatic cancer, showed an elevation of diagnostic efficiency compared with single assay. These results indicate that BFP is superior to other tumor markers for serological diagnosis of various cancer and also available for the combined assays.
 ...
PMID:[Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (2) Comparison and combination of BFP with other tumor markers]. 245 40

Tumor tissues obtained from 5 cases of malignant mesothelioma and from 5 cases of primary adenocarcinoma of the lung have been studied on staining with the sialyl SSEA-1 antibody by the PAP method. Results in all cases of a malignant mesothelioma (both Epithelioid and Sarcomatous pattern) were absolutely negative. All cases of lung cancer, however, were positive, though in differing degrees. In evaluating a malignant mesothelioma, many reports have indicated that the negativity of CEA staining is useful in achieving the differential diagnosis from lung cancer. The sensitivity of the staining by sialyl SSEA-1 was found to be far better than that of CEA in examining either malignant mesothelioma or lung cancer. Thus, we found that not only CEA but also sialyl SSEA-1 antigen staining was useful for the diagnosing of a malignant mesothelioma.
 ...
PMID:[A comparison of the sialyl SSEA-1 antigen and CEA in the histology of malignant mesothelioma, with special reference to adenocarcinoma of the lung]. 246 47

CA130 is a glycoprotein which is recognized by monoclonal antibodies-(130-22 and 145-9) produced by immunization with human lung adenocarcinoma cell line (PC-9). CA130 is considered to be a new tumor marker, different from CA125, since it has a separate antigenic determinant. We used the D-7111 kit (Daiichi Radioisotope Laboratories, Ltd.) to measure the serum level of CA130 in 290 patients with lung cancer, 171 patients with noncancerous lung disease (N-CLD) and 93 healthy adults. In addition, CEA, CA19-9, CA125 and sialyl SSEA-1 antigen (SLX) were also measured for the same serum samples when possible. The cutoff level for CA130 was 35 U/ml. The overall positive rates for CA130 were 32% in the lung cancer patients, 23% in the N-CLD patients and 0% in the healthy adults. The positive rate in the lung cancer patients was significantly higher than in the N-CLD patients (p less than 0.05). As a function of the histological type of lung cancer, the positive rates for CA130 were 44% in 120 patients with adenocarcinoma, 17% in 115 patients with squamous cell carcinoma, 33% in 36 patients with small cell carcinoma, 42% in 12 patients with large cell carcinoma and 29% in 7 patients with miscellaneous cell type. The positive rate in the patients with adenocarcinoma was significantly higher than in the patients with squamous cell carcinoma (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical evaluation of serum CA130 in patients with lung cancer]. 257 55

The serum-CEA (S-CEA) levels were assessed in different lung diseases. The highest levels were seen in lung cancer. Elevated levels of S-CEA were also seen in pneumonia which decreased after withdrawal of inflammatory changes. S-CEA in sarcoidosis pulmonary tuberculosis and chronic bronchitis did not exceed the upper normal limits. Serum CEA can be used to monitor therapy of lung cancer.
 ...
PMID:[Carcinoembryonic antigen (CEA) in the blood serum of patients with bronchogenic carcinoma and selected diseases of the respiratory tract]. 262 50

Serum and BAL CEA levels were determined in stage I (WHO scale) lung cancer patients. The immuno-enzyme assay for the quantitative determination of CEA according to enzyme-linked immunosorbent assay (ELISA) principle was used. Eight smokers without symptoms of respiratory disease served as a control group. The CEA levels were also determined in 48 patients with chronic bronchitis to evaluate the influence the role of the inflammatory processes of the respiratory tract in producing CAE. All determined serum, and BAL fluid CEA levels were related to total protein and albumin for comparison of both media. It was shown that the BAL fluid CEA levels in lung cancer patients exceeded 10-fold the control levels, and twice fold the levels found in chronic bronchitis. It must be emphasized that serum levels were within normal limits in all analysed groups. The concentration of CEA expressed as ratio to total protein and albumin supported a diagnostic usefulness of CEA in BAL and indicated a slight modification of it by inflammatory process.
 ...
PMID:[Concentration of carcinoembryonic antigen in the serum and bronchoalveolar lavage fluid in patients with lung cancer]. 263 45

Tumour markers are often circulating tumour-associated indicators of tumour development. As such they are not suitable for tumour screening and localization, but valuable as adjuncts for medical follow-up care of tumour patients, where their serum level alterations may anticipate the clinical detection of tumour behaviour by a lead time of 1 to 6 months before other methods. The following tumour may be controlled by established markers: endocrine tumours by NSE, calcitonin, parathormone, 5-HIAA, catecholamines/metabolites etc.; head-neck tumours: SCC, CEA; thyroid carcinoma: TG, calcitonin; lung cancer: CEA, NSE, SCC; liver cancer: AFP (PLC), CA 19-9 (cholangiocell.), CEA (secondary): biliary tract and pancreatic cancer: CA 19-9; colorectal carcinoma: CEA, CA 19-9; squamous cell carcinoma (ENT, oesophagus, anal): SCC; breast cancer: CEA and CA 15-3; ovarian cancer: CA 125 (epithelial), CA 19-9 (mucinous); germ cell tumours (ovary including trophoblastic tumours/testes): AFP and HCG; prostatic cancer: PAP and PSA; bladder cancer: TPA.
 ...
PMID:[Clinical relevance of tumor markers]. 267 6


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>